Guidelines for Treatment
of Hyperlipidia and CAD
Coronary heart disease (CAD) is one of the leading causes of morbidity and mortality for both women and men in the US and worldwide. CAD prevention is based on removing or reducing modifiable risk factors that contribute to its development (Jellinger et al 2017). Hyperlipidemia is one of these modifiable risk factors. The guidelines for the treatment of hyperlipidemia and CAD are published by various agencies. However, the latest guidelines have been developed by the American Association of Clinical Endocrinologists (AACE). The 2017 AACE guidelines provide 87 recommendations on array of clinical scenarios faced in clinical practice. These guidelines adhere to…………..
Assignment status: Solved by our experts